Zacks Premium - Zacks Premium提供多种方式帮助投资者充分利用股市并增强投资信心[1] - Zacks Premium包括Zacks Rank和Zacks Industry Rank的每日更新，Zacks 1 Rank List的完整访问权限，股票研究报告和高级股票筛选[2] - Zacks Style Scores是与Zacks Rank一起开发的互补指标，根据价值、增长和动量特征对股票进行评级，帮助投资者选择未来30天内市场表现最佳的股票[3]

A month has gone by since the last earnings report for Amedisys (AMED) . Shares have lost about 2.5% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Amedisys due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Amedisys Q4 Earnings Miss Estimates, Margins RiseAmedisys, ...

One stock that might be an intriguing choice for investors right now is Amedisys, Inc. (AMED) . This is because this security in the Medical - Outpatient and Home Healthcare space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking ...

Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Amedisys (AMED) and U.S. Physical Therapy (USPH) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and est ...

营收情况 - Amedisys (AMED)在2023年12月结束的季度报告了5.7079亿美元的营收，同比增长1.6%[1] - 公司报告的营收与Zacks Consensus Estimate的5.6485亿美元相比，出乎意料地增加了1.05%[2] 每股收益 - 每股收益为0.94美元，与去年同期的1.16美元相比有所下降[1] - 公司的每股收益也出现了-9.62%的意外，与预期的1.04美元相比[2] 业绩表现 - Amedisys在最近报告的季度中在一些关键指标上表现良好，包括家庭健康的净服务收入、高级护理的净服务收入和临终关怀的净服务收入[5][6][7] 股票表现 - Amedisys的股票在过去一个月中的表现为-1.1%，而Zacks S&P 500 composite指数为+3%[8]

Amedisys盈利情况 - Amedisys在上一季度每股收益为0.94美元，低于Zacks Consensus Estimate的1.04美元[1] - Amedisys在过去四个季度中两次超过了市场预期的每股收益[2] - Amedisys在2023年12月份的季度营收为5.7079亿美元，超过了Zacks Consensus Estimate[3] - Amedisys未来季度和当前财年的盈利预期为每股0.95美元和每股4.49美元[9] Amedisys股价表现 - Amedisys股价自年初以来下跌了1.4%，而标普500指数上涨了4.3%[5] - Amedisys的盈利前景将影响股价的短期走势[6] - Zacks Rank显示Amedisys的盈利预期趋势良好，目前为买入评级[8] 行业前景影响 - 医疗-门诊和家庭保健行业的前景将影响Amedisys的股价表现[10]

| --- | --- | |-------|-------------------------------------------------------------------------| | | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | | | FORM 10-K | (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24260 AMEDISYS, INC. (E ...

Exhibit 99.1 AMEDISYS REPORTS FOURTH QUARTER AND YEAR-END 2023 FINANCIAL RESULTS BATON ROUGE, Louisiana (February 21, 2024) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year ended December 31, 2023. Three-Month Periods Ended December 31, 2023 and 2022 ◦ Net service revenue increased $8.8 million to $570.8 million compared to $562.0 million in 2022. Prior year included $15.9 million of net service revenue from our personal care business which was diveste ...

The market expects Amedisys (AMED) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they mi ...

BATON ROUGE, La., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care in the home, is now offering advanced molecular testing to its care centers nationwide. This innovative collaboration with Patient Choice Laboratories utilizes molecular testing for the swift and precise identification of pathogens in urine, respiratory and wound infections. By leveraging the latest in diagnostic technology, Amedisys aims to improve the quality of ...